novo nordisk glp-1 drugs Novo, Lilly weight-loss should be first option obesity treatments, European doctors say Novo's patent expires in India:

Approved 20 years ago as a treatment for diabetes, GLP-1 drugs have been found also to help patients significantly reduce weight

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection

Glucagon-like peptide-1 (GLP-1) mimetics are a class of recently developed diabetes therapy that do not lead to hypoglycemic, but some reports have suggested a relationship between GLP-1 mimetics and ketogenesis

Glucagon-like peptide-1 (GLP-1) receptor agonists, introduced in 2005, have become crucial in managing type 2 diabetes mellitus (T2DM) by regulating g..